Aerie Pharmaceuticals (Aerie Pharmaceuticals) Net Income (Continuing Operations) : $-36.6 Mil (TTM As of Sep. 2022)

View and export this data going back to 2013. Start your Free Trial

What is Aerie Pharmaceuticals Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Aerie Pharmaceuticals's Net Income (Continuing Operations) for the three months ended in Sep. 2022 was $-26.8 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Sep. 2022 was $-36.6 Mil.

Aerie Pharmaceuticals Net Income (Continuing Operations) Historical Data

The historical data trend for Aerie Pharmaceuticals's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aerie Pharmaceuticals Net Income (Continuing Operations) Chart

Aerie Pharmaceuticals Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Net Income (Continuing Operations)

Get a 7-Day Free Trial

-145.11

-232.57

-199.58

-183.10

-74.81

Aerie Pharmaceuticals Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Net Income (Continuing Operations)	Get a 7-Day Free Trial															-39.69	45.53	-35.89	-19.37	-26.83

Aerie Pharmaceuticals Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-36.6 Mil.

Aerie Pharmaceuticals (NAS:AERI) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Aerie Pharmaceuticals Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of Aerie Pharmaceuticals's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.

Aerie Pharmaceuticals (Aerie Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aerie Pharmaceuticals Inc (NAS:AERI) » Definitions » Net Income (Continuing Operations)

Comparable Companies

Traded in Other Exchanges

N/A

Address

4301 Emperor Boulevard, Suite 400, Durham, NC, USA, 27703

Website

https://www.aeriepharma.com

Aerie Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is focused on the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases, and retinal diseases. Its main products are Rhopressa and Roklatan. The company mainly operates in North America.

Executives

Peter Frederick Lang	officer: Chief Financial Officer	AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM NC 27703
Raj Kannan	director, officer: Chief Executive Officer	C/O CHIASMA, INC. 460 TOTTEN POND RD, SUITE 530, WALTHAM MA 02451
Jeffrey Calabrese	officer: Vice President of Finance	AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM NC 27703
Kathleen Mcginley	officer: CHRO & VP, Corp Services	15279 ALTON PARKWAY SUITE 100, IRVINE CA 92618
Christopher Staten	officer: Interim CFO	AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
Casey C. Kopczynski	officer: Chief Scientific Officer	135 U.S. HIGHWAY 206, SUITE 15, BEDMINSTER NJ 07921
Peter J Mcdonnell	director	2525 DUPONT DRIVE, IRVINE CA 92612
Gerald D. Cagle	director	135 U.S. HIGHWAY 206, SUITE 15, BEDMINSTER NJ 07921
Foresite Capital Fund Ii, L.p.	10 percent owner	600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
David Hollander	officer: Chief R&D Officer	C/O AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM NC 27703
Richard J Rubino	officer: Chief Financial Officer
Vicente Jr Anido	director, officer: Chief Executive Officer	1621 BAYSIDE DR, CORONA DEL MAR CA 92625
Foresite Capital Management Iv, Llc	10 percent owner	900 LARKSPUR LANDING CIRCLE, SUITE 150, LARKSPUR CA 94939
Foresite Capital Fund Iv, L.p.	10 percent owner	600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Thomas A Mitro	officer: President and COO	15279 ALTON PARKWAY SUITE #100, IRVINE CA 92618